Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.

Critical care (London, England)

Volumn 9, Issue 5, 2005, Pages

  Rondon, Eliseo ^a   Venkataraman, Ramesh ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFELIMOMAB; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; EPIDEMIOLOGY; HUMAN; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

ANTIBODIES, MONOCLONAL; CAUSE OF DEATH; EPIDEMIOLOGIC METHODS; HUMANS; INTERLEUKIN-6; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747614567     PISSN: None     EISSN: 1466609X     Source Type: Journal    
DOI: None     Document Type: Article

References (0)